schizophrenia. Schizophrenia
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will take Atorvastatin tablet (20 milligram) once daily via oral route for 6 weeks. This drug will be produced by the Pharmacology department
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: Diagnosis of schizophrenia based on DSM-5 patients between 18 and 64 years Informed consent by the patients and a member of his/her family Minimum eighth grade education No psychiatric comorbidity No medical comorbidity No substance use, except for cigarettes No history of hypersensitivity reaction or intolerable side effects with Atorvastatin No concomitant drugs that they interact with Atorvastatin (Anti-inflammatory drugs such as Aspirin and Ibuprofen, Thiazide diuretics, weight-loss drugs, anti-fungal drugs, Macrolids, Colchicin, Protease inhibitors) No pregnancy or breastfeeding (for women) No history of major head trauma No participation in other study in the time of this study No major cognitive deficits comorbidity
Exclusion criteria
Exclusion criteria: Failure to the patient or his/her family to continue the study Occurrence of any serious side effects during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive state. Timepoint: At the outset of the study (before intervention), at 21 days 42 days after starting Atorvastatin. Method of measurement: PANSS test, Stroop test, Digit span test, Verbal fluency test, Wechsler test, Wisconsin Card Sorting test, and Trial making test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Positive and negative symptoms score. Timepoint: At the outset of the study (before intervention), and at 3 and 6 weeks after starting Atorvastatin. Method of measurement: Positive and Negative Symptoms Scale test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Soleimani
Mashhad University of Medical Sciences
Outcome results
None listed